Código QR (código de barras bidimensional)

Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

ObjectiveTo assess the pharmacokinetics and pharmacodynamics of the long-acting terminal complement 5 (C5) inhibitor ravulizumab in adults with anti-aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) in the phase 3, open-label CHAMPION-NMOSD trial (NCT04201262).Meth...

ver descrição completa

Na minha lista:
Principais autores: Stephan Ortiz, Sean J. Pittock, Achim Berthele, Michael Levy, Ichiro Nakashima, Celia Oreja-Guevara, Kerstin Allen, Yasmin Mashhoon, Becky Parks, Ho Jin Kim
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2024-01-01
coleção:Frontiers in Neurology
Assuntos:
autoimmune
complement
exposure-response analysis
neuromyelitis optica spectrum disorder
pharmacokinetics
pharmacodynamics
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fneur.2024.1332890/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados